First Trust Nasdaq Pharmaceuticals ETF Rating $27.81 +0.14 (+0.49%) Closing price 03:52 PM EasternExtended Trading$27.86 +0.05 (+0.19%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock First Trust Nasdaq Pharmaceuticals ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FTXH Aggregate RatingModerate Buy 2.54Holdings in FTXH have an aggregate rating of Moderate Buy based on 459 analyst ratings issued in the past year covering 25 companies (87.1% of the portfolio).FTXH Aggregate Price Target$27.81High Prediction$27.81Average Prediction$27.81Low Prediction$27.81Holdings in FTXH have an aggregate price target of $27.81 and a range of $27.81 to $27.81 covering 25 companies (87.1% of the portfolio).FTXH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy14 Moderate Buy rating(s)Hold8 Hold rating(s)Reduce2 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust Nasdaq Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 FTXH Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings8.05%JNJJohnson & Johnson$181.63+1.1%4.6902 of 5 stars2.67$181.40 -0.1%21Positive News7.79%ABBVAbbVie$222.93+1.1%4.7765 of 5 stars2.93$223.45 0.2%27Trending News6.74%PFEPfizer$23.84+0.3%4.9897 of 5 stars2.39$28.12 17.9%18Trending NewsAnalyst Downgrade6.70%MRKMerck & Co., Inc.$78.46-0.1%4.9993 of 5 stars2.33$106.41 35.6%21Positive News5.78%BMYBristol Myers Squibb$44.124.8764 of 5 stars2.24$56.38 27.8%21Positive News4.72%UTHRUnited Therapeutics$424.31-1.9%4.5941 of 5 stars2.71$449.57 6.0%14Analyst ForecastInsider Trade4.03%VTRSViatris$9.62+1.1%1.5662 of 5 stars1.80$10.40 8.1%53.85%BIIBBiogen$138.52+0.8%4.667 of 5 stars2.35$182.04 31.4%31Analyst Upgrade3.74%GILDGilead Sciences$112.62+0.5%4.9169 of 5 stars2.89$117.17 4.0%283.34%AMGNAmgen$273.97+0.4%4.7618 of 5 stars2.30$309.70 13.0%20Positive NewsAnalyst Forecast3.30%ZTSZoetis$142.97-0.4%4.8206 of 5 stars2.56$200.88 40.5%9Positive News3.27%JAZZJazz Pharmaceuticals$129.02+1.6%4.334 of 5 stars2.88$178.93 38.7%16Positive News3.05%LLYEli Lilly and Company$725.54+0.1%4.9985 of 5 stars2.67$939.61 29.5%24Trending News2.98%REGNRegeneron Pharmaceuticals$560.75-0.6%4.7623 of 5 stars2.82$817.67 45.8%28Positive News2.82%ELANElanco Animal Health$19.63+0.1%2.5155 of 5 stars2.78$18.33 -6.6%9Positive News2.77%MEDPMedpace$500.76+0.8%4.1045 of 5 stars1.94$422.27 -15.7%171.99%EXELExelixis$40.57+3.9%4.7086 of 5 stars2.61$44.42 9.5%23Positive News1.97%CRLCharles River Laboratories International$146.88-1.1%4.6203 of 5 stars2.31$177.07 20.6%16Analyst Upgrade1.92%OGNOrganon & Co.$10.35+1.3%4.6291 of 5 stars2.80$17.33 67.6%5Positive News1.85%ILMNIllumina$91.87+0.2%4.8278 of 5 stars2.21$123.06 33.9%19Positive News1.82%HALOHalozyme Therapeutics$73.29-0.6%4.423 of 5 stars2.42$69.89 -4.6%121.67%NBIXNeurocrine Biosciences$140.27-1.2%4.6542 of 5 stars2.85$161.89 15.4%200.99%AMRXAMNEAL PHARMACEUTICALS$9.87+1.2%2.7815 of 5 stars3.00$12.00 21.6%50.99%BMRNBioMarin Pharmaceutical$54.02+0.3%4.9235 of 5 stars2.64$92.60 71.4%220.97%ALNYAlnylam Pharmaceuticals$447.49+0.2%3.6511 of 5 stars2.86$439.58 -1.8%28 This page (NASDAQ:FTXH) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
